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Abstract 
Background: In Japan, cognitive behavioral therapy (CBT) for panic disorder (PD) is not well established. Therefore, 
a feasibility study of the clinical effectiveness and cost-effectiveness of CBT for PD in a Japanese clinical setting is 
urgently required. This was a pilot uncontrolled trial and the intervention consisted of a 16-week CBT program. The 
primary outcome was Panic Disorder Severity Scale (PDSS) scores. Quality of life was assessed using the EuroQol’s 
EQ-5D questionnaire. Assessments were conducted at baseline, 8 weeks, and at the end of the study. Fifteen subjects 
completed outcome measures at all assessment points.
Results: At post-CBT, the mean reduction in PDSS scores from baseline was −6.6 (95 % CI 3.80 to −9.40, p < 0.001) 
with a Cohen’s d = 1.77 (95 % CI 0.88–2.55). Ten (66.7 %) participants achieved a 40 % or greater reduction in PDSS. By 
calculating areas under the curve for EQ-5D index changes, we estimated that patients gained a minimum of 0.102 
QALYs per 1 year due to the CBT.
Conclusions: This study demonstrated that individual CBT for PD may be useful in Japanese clinical settings but 
further randomized control trials are needed.
Trial registration: UMIN-CTR UMIN000022693 (retrospectively registered)
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Background
Panic disorder (PD) is an anxiety disorder character-
ized by recurring panic attacks [1]. PD is one of the most 
prevalent psychiatric disorders in developed and devel-
oping countries [2], and its prevalence and incidence 
rates are very similar across the globe [3]. In Japan, the 
prevalence of PD is 0.8 % [4]. PD is often comorbid with 
other psychological disorders (as with many anxiety and 
depressive disorders), and is associated with functional 
disability (e.g., social and occupational impairment [2]), 
low health-related quality of life, and economic burden 
[5, 6].
Both pharmacotherapy and psychotherapy have been 
recommended as first-line treatments for PD [7]. Cogni-
tive behavioral therapy (CBT) may be more effective than 
pharmacotherapy, while combining pharmacotherapy 
with CBT is superior to the use of antidepressants alone 
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[8]. Furthermore, CBT is more cost-effective for treating 
PD compared to the use of serotonin re-uptake inhibitors 
(SSRIs) only [9, 10].
Notably, randomized controlled trials in Western coun-
tries have consistently indicated that individual CBT 
alone is effective for treating PD [11–13]. Furthermore, 
individually administered CBT appears to be more effec-
tive than group therapy [13]. However, in Japan, CBT’s 
effectiveness for PD has not yet been well established. 
Therefore, a feasibility study of individual CBT for PD in 
Japanese clinical settings is urgently required. A feasibil-
ity study would clarify whether CBT can achieve favora-
ble treatment outcomes in Japanese PD patients, and 
whether it is sufficiently cost-effective.
The first purpose of this uncontrolled trial is to clarify 
the clinical effectiveness of an individual CBT program 
for PD in Japanese clinical settings. As pointed out by 
Kaczkurkin and Foa [14], exposure and cognitive therapy 
are two of the most commonly used CBT methods used 
to treat anxiety disorders. In contrast, our CBT program 
for PD is based on cognitive therapy that utilizes the 
Clark et  al. [15] model for PD and the Clark and Wells 
[16] model for social anxiety disorder. Furthermore, it 
includes behavioral experiments, as with interoceptive 
and agoraphobic exposure.
In terms of cost-effectiveness, CBT and CBT com-
bined with an SSRI are considered more cost-effective 
for treating PD as compared to an SSRI only [17]. An 
effective indicator of cost-effectiveness used in the past 
is the quality-adjusted life year (QALY), which com-
bines the outcomes of duration and quality of life in the 
assessment of medical interventions [18]. Thus, the sec-
ond purpose of this study was to estimate the number of 




This study was an uncontrolled and unblinded clinical 
trial. Because this study was the first trial employing an 
individual CBT intervention for PD in Japan, we believed 
an uncontrolled design examining the baseline predic-
tors to be appropriate [19]. Patients were recruited and 
screened for a diagnosis of PD via an interview before 
undergoing the CBT intervention. Patients received the 
CBT intervention for 16  weeks, and assessments were 
conducted before the first session (at week 0; pre-CBT), 
after the eighth session (week 8; mid-CBT), and after the 
final session (week 16; post-CBT). This study protocol 
was approved by the Ethics Committee of the Chiba Uni-
versity Graduate School of Medicine (Reference number: 
1710) and was registered in the national UMIN Clinical 
Trials registry (ID: UMIN000022693).
Participants
This study was conducted at three clinics: the outpa-
tient clinic at Chiba University Hospital, Inada Clinic, 
and Clinic Adachi. Participants were recruited through 
clinical referrals and web-based advertisements between 
April 2014 and March 2015. Written informed consent 
was obtained from all patients before any assessments 
were made. Criteria for inclusion in this study were a pri-
mary diagnosis of PD according to DSM-5 criteria, being 
between 18 and 65 years of age, and having at least mod-
erately severe PD (according to a Panic Disorder Sever-
ity Scale [PDSS] score ≥8; [20]). Comorbid diagnoses 
were permitted if they were clearly secondary (i.e., the 
PD symptoms were both the most severe and the most 
impairing). The exclusion criteria were having psychosis, 
pervasive developmental disorders/mental retardation, a 
currently high risk of suicide, substance abuse or depend-
ence in the past 12 months, or antisocial personality dis-
order. All patients were evaluated by a psychiatrist using 
the MINI International Neuropsychiatric Interview [21, 
22]. Treatment history was confirmed by a therapist and 
chart review.
Intervention
The individual CBT intervention was conducted in 16 
weekly 50-min sessions. We developed the CBT program 
for PD to focus on changing catastrophic misinterpre-
tations of bodily sensations, as per the Clark et  al. [15] 
model. We also applied several concepts from the Clark 
and Wells model for social anxiety disorder [16], because 
in two recent studies of ours on the effectiveness of CBT 
for social anxiety disorder—by a single arm trial [23] and 
a randomized controlled trial [24, 25]—we found such 
concepts to be effective not only for social anxiety dis-
order, but also for PD, which are both highly common 
anxiety disorders. Specifically, we added the concepts of 
the detrimental effects of safety behaviors, attentional 
bias modification (attentional shift training), behavioral 
experiments including interoceptive exposure (system-
atic exposure to body sensations), imagery and memory 
rescripting, and reconsideration of worry/rumination 
to strengthen anticipatory anxiety. The main treatment 
steps were as follows:
 a. Development of an individualized version of the cog-
nitive-behavioral model of PD;
 b. Conducting role-play-based behavioral experiments 
with and without safety behaviors;
 c. Restructuring catastrophic self-imagery induced by 
bodily sensations or catastrophic misinterpretations 
of bodily sensations [15];
 d. Practicing external focus and the shifting of atten-
tion;
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 e. Behavioral experiments to test negative catastrophic 
beliefs [26];
 f. Rescripting early memories linked to negative images 
in panic situations;
 g. Modifying problematic pre- and post-event process-
ing;
 h. Discussing the difference between self-beliefs and 
other people’s beliefs (reflected in survey results);
 i. Dealing with the remaining assumptions (schema 
work); and
 j. Preventing relapse;
Furthermore, we assigned homework after every ses-
sion; this was meant to help patients test in daily life their 
beliefs about each treatment theme that they had identi-
fied collaboratively with the therapist.
Quality control
The CBT was delivered by 9 therapists (7 clinical psy-
chologists and 2 psychiatrists) who were experienced in 
delivering CBT for PD. To confirm therapists’ adherence 
to the protocol and assist with the planning of future ses-
sions for each treatment, all of the therapists attended 
weekly group supervision sessions with other therapists 
and with a senior supervisor (ES). The senior supervisor 
also checked the quality of the CBT delivered by thera-
pists using the cognitive therapy scale-revised [27].
Outcomes
The primary outcome measure was the self-reported 
severity of PD, as measured by the PDSS [20]. The self-
report form of the PDSS [28] measures the severity of PD 
on a 5-point Likert-type scale ranging from 0 (not severe) 
to 4 (severe); as such, higher scores indicate more severe 
PD. This scale was adapted from the original, clinician-
administered scale [20]; it is the most frequently used 
scale for the assessment of PD. The Japanese version of 
the PDSS was developed by Katagami [29].
In order to ensure that our results are comparable with 
those of previous studies of CBT, patients also completed 
additional self-report measures of PD severity: the Panic 
and Agoraphobia Scale (PAS), 9-item patient health 
questionnaire (PHQ-9), 7-item generalized anxiety disor-
der scale (GAD-7), and Brief Fear of Negative Evaluation 
Scale (BFNE). The Japanese versions of all of these meas-
ures have good reliability and validity.
The PAS [30] comprises 13 items that measure the 
severity of panic symptoms on a 5-point Likert-type 
scale. The Japanese version of the PAS was developed by 
Kaiya, Yoshida, and Kumano [31].
The PHQ-9 [32] contains nine items assessing severity 
of depression rated on a 4-point Likert-type scale. The 
Japanese version of the PHQ-9 was developed by Mura-
matsu et al. [33].
The GAD-7 [34] comprises seven items that measure 
the severity of generalized anxiety disorder on a 4-point 
Likert-type scale. The Japanese version of the GAD-7 was 
developed by Muramatsu [35].
The BFNE [36] contains 12 items that measure social 
fears on a 5-point Likert-type scale. BFNE is specifi-
cally intended to measure the social discomfort resulting 
from perceptions of being negatively evaluated by oth-
ers, which is also relevant to PD. This was a short-form 
version adapted from the original 30-item scale [37]. The 
Japanese version of the BFNE was developed by Sasagawa 
et al. [38].
Patients also completed the 3-level version of Euro-
Qol’s EQ-5D questionnaire. The EQ-5D [39] contains five 
items that assess quality of life on a 3-point Likert-type 
scale ranging from 1 (not severe) to 3 (severe). The Jap-
anese version of the EQ-5D was developed by Tsuchiya 
et al. [40]. The EQ-5D is the most commonly used scale 
internationally for calculating QALYs. QALYs are often 
used in cost-utility analyses as the health outcome of 
choice; they are typically estimated via area-under-the-
curve (AUC) analysis, which involves summing the areas 
of the distribution shapes for utility scores over the study 
period [41]. In the present study, QALYs were assessed 
using the EQ-5D index, an indicator of patient health sta-
tus. This index is calculated by transforming the EQ-5D 
dimension scores into a single summary score ranging 
from 0 to 1 (1 =  full health) by applying a formula cre-
ated by the EuroQol Group [39]. Patients completed the 
questionnaires at home.
Statistical analysis
All statistical tests were two-tailed, and an alpha level of 
0.05 was employed. All data were analyzed using SPSS for 
Windows version 21 (SPSS Inc., Chicago, IL, USA). The 
outcomes of the CBT for PD were quantified as follows. 
First, regarding our primary outcome (PDSS scores), we 
analyzed changes between pre-CBT and the other two time 
points (mid-CBT and post-CBT) using repeated-meas-
ures, within-subjects ANOVAs. Furthermore, we estab-
lished the following threshold for response and remission 
[20]: individuals were defined as “treatment responders” if 
they exhibited a 40 % or greater reduction in PDSS score 
over the course of treatment, while they were considered 
“in remission” if they had a score of 7 or less on the PDSS 
after the intervention [20]. We also calculated Cohen’s d, a 
measure of effect size, as the difference between the means 
divided by the pooled SD. According to Cohen [42], effect 
sizes are categorized as follows: small (0.20–0.49), medium 
(0.50–0.79), and large (0.80 and above).
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To measure the cost-effectiveness of the CBT, we cal-
culated QALYs at mid- and post-CBT using the AUC 
of changes in EQ-5D index from baseline [39]. Because 
of the lack of follow-up data, we estimated QALYs at 
12  months after the start of CBT in the following two 
conditions: the worst condition, wherein the EQ-5D 
index had decreased to baseline at 12  months; and the 
best condition, wherein the EQ-5D index remained high 
at 12  months. Finally, to examine the other secondary 
outcomes, we compared the PAS, PHQ-9, GAD-7, and 
BFNE scores between pre-, mid- and post-CBT.
Results
Participant characteristics
All participating therapists adhered to the treatment pro-
tocol under supervision. Of the 17 subjects screened, 15 
were eligible for participation and were recruited.
There were no dropouts over the course of the inter-
vention. After enrolling in the study, no patients dropped 
out (Fig. 1). Table 1 shows the baseline demographic and 
clinical characteristics of the 15 patients. There were 13 
women (80 %), and patients’ mean age was 38.6 years; 3 
patients (20 %) were unemployed and 6 (40 %) were sin-
gle, and their mean length of education was 12.7 years.
According to the Organisation for Economic Co-Opera-
tion and Development’s “Education At a Glance 2010,” the 
ratio of university graduates in the Japanese population 
ranges from 55.1 to 26.0  % among young (25–34  years 
old) and old- and middle-aged individuals (55–64  years 
old), respectively. Because the proportion of university 
graduates in this study was 53 %, which suggests that the 
sample was similar to the rate in the general population.
All participants met the DSM-5 diagnostic criteria for 
PD (mean duration of illness 10.8  years). Furthermore, 
13 patients (87 %) also met the criteria for agoraphobia, 1 
patient (7 %) for major depressive disorder, and 3 patients 
(20  %) for other anxiety disorders. Among the three 
patients with other anxiety disorders, two had general-
ized anxiety disorder, one patient had comorbid gener-
alized anxiety disorder and social anxiety disorder. Nine 
patients (60  %) took antidepressants. Specifically, five 
patients took sertraline, one took escitalopram, one took 
paroxetine, one took both paroxetine and duloxetine, one 
took both sertraline and imipramine. Notably, all nine of 
Fig. 1 Participant flow diagram. PDSS Panic Disorder Severity Scale, CBT cognitive behavioral therapy
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these patients remained symptomatic despite adequate 
treatment with at least one SSRI at the maximum dose 
for at least 12 weeks; in other words, they exhibited intol-
erance to at least one SSRI [25]. There were no changes in 
pharmacotherapy during the CBT intervention.
Primary outcome
Figure  2 and Table  2 show the outcome measures at 
each time point. The mean total PDSS score decreased 
from 12.1 at pre-CBT to 5.5 at post-CBT. A repeated-
measures ANOVA revealed a significant main effect of 
time point on the PDSS total score, F (2, 42)  =  12.39, 
p < 0.001 (see Fig. 2). Notably, 10 patients (66.7 %) met 
the criteria for remission of PD at post-CBT [20], and 10 
patients (66.7 %) were judged to be responders [43]. PD 
remission was defined as having a score of seven or less 
on the PDSS, whereas a responder was defined as some-
one who showed a 40  % or greater reduction in PDSS 
score. In this study, patients overlapped between these 
groups.
As shown in Table  3, the pre-to-post-CBT effect size 
(d = 1.77) was large, and provided comparable effective-
ness to calculated for a previous study on individual CBT 
for PD [9].
Secondary outcomes
PAS, PHQ‑9, GAD‑7, and BFNE
The mean total score of the PAS decreased from 23.5 at 
pre-CBT to 11.6 at post-CBT. We also noted significant 
improvements in the PHQ-9 and GAD-7 between pre- 
and post-CBT scores (p  <  0.05). Although the BFNE 
scores did not significantly differ between the time points 
(see Table 2), they nevertheless showed large pre-to-post-
CBT effect sizes (d = 0.85). The effect sizes for the PAS, 
GAD-7, and PHQ-9 score changes were also large, at 
2.00, 0.95, and 0.86, respectively.
EQ‑5D and QALYs
Table  4 shows the changes in each dimension score of 
the EQ-5D. Although all five dimension scores improved, 
only those of usual activities and pain/discomfort were 
significant.
The mean changes in the EQ-5D index from baseline 
were 0.143 at mid-CBT and 0.199 at post-CBT. Accord-
ing to the AUCs, the change in QALYs from baseline 
to post-CBT (i.e., 16  weeks) was estimated as 0.0364 
QALYs. Under the worst condition—namely, that EQ-5D 
deteriorated to baseline at 12  months—the change in 
QALYs from baseline to 12  months was estimated as 
0.102 QALYs. Under the best conditions—namely, that 
EQ-5D maintained a high level at 12 months—the change 
Table 1 Baseline demographic and  clinical characteristics 
(N = 15)
PD panic disorder, BZ benzodiazepine, AD antidepressant, M.I.N.I. Mini 
International Neuropsychiatric Interview
Variable Value
Female, n (%) 13 (80)
Age (years), mean (SD) 38.6 (9.6)
Comorbid agoraphobia, n (%) (M.I.N.I.) 13 (87)
Comorbid axis I diagnosis, n (%) (M.I.N.I.)
 No comorbid condition (PD only) 12 (80)
 Major depression 1 (7)
 Other anxiety disorder 3 (20)
Age of onset (years), mean (SD) 27.8 (9.5)
Duration of PD, years, mean (SD) 10.8 (9.5)
Employ status, n (%)
 Employed full-time 5 (33)
 Full-time student 0 (0)
 Part-time/homemaker 7 (47)
 Unemployed 3 (20)
Marital status, n (%)
 Single 6 (40)
 Married 8 (53)
 Divorced 1 (7)
Educational background, n (%)
 Junior high school 0 (0)
 High school 2 (13)
 <3 years of college/university 8 (53)
 ≥3 years of college/university 5 (33)
Length of education (years), mean (SD) 12.7 (2.1)
Current medication, n (%)
 BZ 11 (73)
 AD 9 (60)
 Both BZ and AD 8 (53)
 No medication 3 (20)
Fig. 2 Estimated change in QALYs from baseline to 52 weeks 
(12 months). QALY quality-adjusted life year
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in QALYs from baseline was estimated as 0.178 QALYs. 
Therefore, between 0.102 and 0.178 QALYs were gained 
per 1 year.
Willingness-to-pay (WTP) values per QALY gained 
have been estimated in a past study as JPY 5 million 
(Japan), KWN 68 million (Republic of Korea), NT$ 2.1 
million (Taiwan), 23,000 UK pounds (United Kingdom), 
AU$ 64,000 (Australia), and US$ 62,000 (United States; 
[44]). Using these values to convert the change in QALYs 
per 1  year into WTP values, we obtained values of JPY 
543,000–889,000 (Japan) and US$ 6740–11,000 (United 
States). Because we provided patients 16 sessions of CBT, 
we estimated that patients would spend JPY 31,800–
52,300 (Japan) and US$ 421–689 (US) per one session 
(50 min) of CBT. Incidentally, patients typically pay only 
around JPY 5000 per one session of CBT in the Japanese 
health insurance system at present.
Discussion
This uncontrolled trial in Japan demonstrated that an 
individual CBT for PD improved PDSS scores, scores 
for various other measures of symptom severity, and 
QALYs. Regarding the primary outcome (the PDDS), 
in the acute phase after treatment, the change in PDSS 
score (effect size = 1.77) that we found was comparable 
to those that we calculated for a previous clinical trial 
conducted by Barlow et al. [10]. Specifically, for that trial, 
the effect sizes (Cohen’s d) for CBT, imipramine, placebo, 
CBT+ imipramine, and CBT+ placebo were 1.24, 1.48, 
0.69, 1.72 and 1.41, respectively. Although our study was 
uncontrolled, these results appear promising.
The developed CBT for PD also appeared to improve 
the PAS score from 23.5 at pre-CBT to 11.6 at post-
CBT (Cohen’s d  =  2.06). King et  al. [45] reported that 
25 patients who received 16 sessions of CBT along with 
medication also showed a significant improvement in 
PAS, decreasing from 27.9 at pre-CBT to 18.6 at post-
CBT (p = 0.012). Seo, Chow, Chung, Rho, and Chae [46] 
also reported that fourteen subjects who completed a 
group-based CBT showed an improvement in PAS from 
24.86 (SD  =  11.98) at pre-CBT to 14.8 (SD  =  6.93) at 
post-CBT (t = 4.55, p = 0.001; Cohen’s d = 1.02). Con-
sidering these previous reports, our CBT appears to have 
high effectiveness in reducing panic symptoms accord-
ing to both the PDSS and PAS. We also noted significant 
reductions in all other secondary outcomes—including 
depression (PHQ-9), generalized anxiety (GAD-7), and 
functional impairment (EQ-5D)—except for social anxi-
ety (BFNE). One possible reason why our CBT for PD 
had little effect on improving social anxiety symptoms 
measured by the BFNE is that the SD of the BFNE score 
was too high because patients with PD had highly vari-
able degrees of social anxiety symptoms.
Table 2 Outcome measures at each assessment point
PDSS Panic Disorder Severity Scale, PAS Panic and Agoraphobia Scale, BFNE Brief Fear of Negative Evaluation Scale, PHQ-9 9-item patient health questionnaire, GAD-7 
7-item generalized anxiety disorder scale
*** p < 0.001, ** p < 0.01
a Mean changes from pre- to post-CBT time points
PDSS PAS PHQ-9 GAD-7 BFNE EQ-5D index
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Pre-CBT 12.1 4.0 23.5 5.8 8.0 3.2 8.7 5.1 42.7 12.4 0.665 0.2
Mid-CBT 7.5 3.3 15.3 3.6 5.4 2.5 5.1 3.6 34.3 12.1 0.823 0.1
Post-CBT 5.5 3.5 11.6 5.7 5.2 3.1 4.5 3.3 31.7 12.6 0.864 0.1
Pre-post CBTa −6.6 4.3*** −11.9 6.6*** −2.8 3.6** −4.2 3.6** −10.9 9.2 (n.s.) 0.199 0.20**
Effect size 1.77 2.06 0.89 0.97 0.87 1.08
Table 3 Comparison of  effect sizes of  CBT on  Panic Disor-
der Severity Scale scores
a Mean represents the average value of one item. The effect sizes reported are 
based on our calculations





Present study 60 min 15 1.7 0.8 1.77
16 weeks 0.6 0.5
Barlow et al. [10]a CBT 77 1.82 1.14 1.04
12 weeks (0.6) (0.7)
Imipramine 83 1.88 1.05 1.23
12 weeks (0.6) (0.8)
Placebo 24 1.88 1.52 0.46
12 weeks (0.5) (0.9)
CBT+ imipramine 65 1.86 0.88 1.48
12 weeks (0.6) (0.7)
CBT+ placebo 63 1.74 0.99 1.22
12 weeks (0.5) (0.7)
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We noted that individual CBT appears to be a feasi-
ble treatment for PD with major depressive disorder or 
other anxiety disorders in Japanese clinical settings. Most 
patients (80 %) in the current study (Table 1) were taking 
benzodiazepines or antidepressants, as Japanese public 
health insurance covers pharmacotherapy but not CBT 
for PD at this time. Heldt et al. [47] reported that CBT for 
pharmacotherapy-resistant patients appears to be effec-
tive in treating PD. In a future randomized controlled 
study on our CBT for PD, we intend to recruit pharma-
cotherapy-resistant patients to guide development of the 
next-step strategies in Japan.
Regarding the results for QALYs, we found that our 
CBT for PD resulted in somewhat higher gains for 
QALYs compared with previous studies on other disor-
ders. For instance, Grochtdreis et  al. [48] reported that 
collaborative care for the treatment of depressive disor-
ders in primary care offered a mean incremental gain of 
0.02 QALYs over 12 months, compared with usual care, 
in their systematic review of 19 cost-effectiveness analy-
ses. McCrone et  al. [49] reported that CBT for chronic 
fatigue syndrome had an incremental gain of 0.05 QALYs 
at 12  months, compared with specialist medical care 
alone, after controlling for baseline utility. Mukuria et al. 
[50] reported that an “improving access to psychologi-
cal therapies” service (covering effective psychological 
therapies for common mental health problems, such 
as depression and anxiety) in the United Kingdom pro-
vided an incremental gain of 0.014 QALYs, while a cost-
benefit analysis of psychological therapies including 
CBT undertaken by Layard et al. [51] estimated that the 
QALYs gained would be 0.11. Overall, our results suggest 
the CBT for PD developed in the present study might be 
highly cost-effective.
Limitations
Overall, although our present study provides highly 
valuable information, it does have some limitations, 
including its small sample size and lack of a control 
group, controlled pharmacotherapy, and long-term 
follow-up data. Without a placebo control group, it 
remains unknown whether the observed improve-
ments in PD severity are merely the result of the natu-
ral course of PD or a result of the intervention. When 
judging the effectiveness of a treatment for PD, it is 
important to consider the placebo effects noted in pre-
vious reports [10, 52–54]. Thus, future studies should 
employ psychological placebo conditions to control for 
nonspecific factors, such as positive outcome expec-
tancy and self-efficacy enhancements related to starting 
to manage their problems. In the near future, we intend 
to conduct a randomized controlled trial that includes 
long-term follow-up to provide greater insight into 
this CBT for PD in routine Japanese practice, based 
on the results of the current study. In this study, 80 % 
of our patients were on medication and thus we can-
not conclude whether the CBT for PD will be effective 
for patients not receiving pharmacotherapy. It would 
thus be necessary to investigate CBT during drug-free 
periods. In the near future, a three-armed randomized 
controlled trial comparing pill placebo (as the control 
group), CBT patients on antidepressants, and CBT 
patients who are drug-free should be designed and 
performed.
Conclusions
Despite the limitations, our results suggest that CBT is 
a feasible treatment that is potentially cost-effective for 
treating PD in Japanese clinical settings. Further rand-
omized controlled trials that address the limitations of 
this study are required.
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Table 4 EQ-5D dimensions at each assessment point
** p < 0.01, * p < 0.05
a Significantly different between pre- and post-CBT periods
Mobility Self-care Usual activities Pain/discomfort Anxiety/depres-
sion
EQ-5D
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Pre-CBT 1.2 0.6 1.1 0.3 1.7 0.6 1.9 0.7 1.9 0.7 0.665 0.2
Mid-CBT 1.3 0.5 1.0 0.0 1.3 0.5 1.5 0.5 1.3 0.5 0.823 0.1
Post-CBT 1.0 0.0 1.0 0.0 1.1 0.4 1.3 0.5 1.5 0.5 0.864 0.1
Pre-post CBTa 0.2 0.1 0.6 ** 0.6 * 0.5 * 0.199 **
ES 0.47 0.00 1.18 0.99 0.66 1.08
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